Study guide
NAION and ischaemic neuropathy comparison
European Board of Ophthalmology Diploma EBOD
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: EBOD Examination, Applications and Regulations
EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals
2 Chapter 2: Physical Optics, Photometry and Lenses
Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid
3 Chapter 3: Instrument Optics, Aberrations and Laser Physics
Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT
4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing
Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses
5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation
Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics
6 Chapter 6: Extraocular Anatomy and Motor Physiology
Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys
7 Chapter 7: Binocular Vision and Amblyopia
Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment
8 Chapter 8: Childhood Assessment and Strabismus Testing
Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts
9 Chapter 9: Esotropia, Exotropia and Vertical Deviations
Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew
10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery
Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles
11 Chapter 11: ROP and Paediatric Ocular Disease
Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding
12 Chapter 12: Ocular Surface Anatomy and Infection
Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis
13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation
Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis
14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies
Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies
15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure
Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency
16 Chapter 16: Surface Reconstruction and Keratoplasty
Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems
17 Chapter 17: Lens Development, Cataract Assessment and Biometry
Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry
18 Chapter 18: IOL Planning and Phacoemulsification
Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques
19 Chapter 19: Cataract Anaesthesia and Surgical Complications
Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO
20 Chapter 20: Corneal and Intraocular Refractive Surgery
Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange
21 Chapter 21: Presbyopia Procedures and Surface Therapeutics
Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin
22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy
Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation
23 Chapter 23: Angle, Disc and Visual-Field Assessment
Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry
24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms
Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure
25 Chapter 25: POAG, Angle Closure and Pigmentary Disease
POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma
26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment
Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers
27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion
Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions
28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy
Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis
29 Chapter 29: Inherited Retina and Electrophysiology
Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina
30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid
AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum
31 Chapter 31: Retinal Breaks and Detachment Repair
PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling
32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma
Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment
33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation
SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation
34 Chapter 34: Infectious Uveitis and Endophthalmitis
Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment
35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy
Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison
36 Chapter 36: Papilloedema, IIH and Afferent Localisation
Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization
37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology
Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies
38 Chapter 38: Central Motor Control and Cranial Nerve Palsies
Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus
39 Chapter 39: Myasthenia and Ocular Myopathy
Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome
40 Chapter 40: Pupillary Pathways and Anisocoria
Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials
41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment
Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation
42 Chapter 42: Lid Repair and Lacrimal Drainage
Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR
43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours
Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma
44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease
Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling
45 Chapter 45: Ocular Trauma and Vascular Systemic Disease
Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease
46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology
Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects
47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations
Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal
NAION and ischaemic neuropathy comparison
Key Takeaways Explain This Topic AI
NAION commonly involves a susceptible optic disc and systemic vascular or sleep-related factors.
Differentiate arteritic disease urgently rather than relying on one appearance or inflammatory-marker result.
Risk-factor care and fellow-eye counselling remain important because no routine treatment reliably reverses every established NAION deficit.
Last updated: October 2026
Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION)
Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) is the most frequent cause of acute optic neuropathy in individuals over the age of 50, with an estimated annual incidence of 2 to 10 per 100,000. It is a multifactorial, localized microvascular hypoperfusion disorder affecting the short posterior ciliary arteries supplying the prelaminar and laminar optic nerve head, in the absence of systemic vasculitis.
Pathogenesis & Structural Predisposition: The "Disc at Risk"
NAION occurs as a consequence of transient microcirculatory hypoperfusion within a structurally vulnerable optic nerve head:
The Anatomical "Disc at Risk" / Crowded Disc: The primary predisposing anatomical factor is a small, crowded optic disc characterized by a small scleral canal and a small or absent physiological cup (cup-to-disc ratio ≤ 0.1 − 0.2 \le 0.1-0.2 ≤ 0.1 − 0.2 ) . In these tightly packed discs, approximately 1.2 million retinal ganglion cell axons squeeze through a rigid, unyielding scleral aperture. When minor ischaemia occurs, the resulting axonal oedema creates a secondary compartment syndrome within the tight scleral ring, compressing adjacent capillaries, worsening ischaemia, and triggering widespread axonal infarction.
Systemic Vascular Risk Factors
Nocturnal Arterial Hypotension: The physiological "nocturnal dip" in systemic blood pressure reduces ocular perfusion pressure ( OPP = Mean Arterial Pressure − Intraocular Pressure \text{OPP} = \text{Mean Arterial Pressure} - \text{Intraocular Pressure} OPP = Mean Arterial Pressure − Intraocular Pressure ). This is frequently exacerbated by taking systemic antihypertensive medications at bedtime.
Systemic Comorbidities: Systemic hypertension, diabetes mellitus, hypercholesterolaemia, cardiovascular disease, and smoking.
Obstructive sleep apnoea: An important association and potentially modifiable systemic risk; screen according to symptoms and clinical context rather than assuming a fixed prevalence.
Phosphodiesterase Type 5 (PDE-5) Inhibitors: Medications such as sildenafil, tadalafil, and vardenafil induce mild systemic vasodilation and nocturnal hypotension; temporal associations with NAION onset have been well documented.
Clinical Presentation & Cardinal Signs
"Morning Discovery": Patients classically discover sudden, painless, unilateral visual loss upon awakening in the morning (reflecting the nocturnal hypotensive insult).
Visual Acuity: Variable, ranging from 20/20 to count fingers (median acuity ~20/60). Over 50% have visual acuity of 20/60 or better.
Visual Field Defect: The hallmark perimetric finding is an altitudinal visual field defect , most commonly an inferior altitudinal scotoma that sharply respects the horizontal midline. This reflects the watershed partition between superior and inferior SPCA supplies.
Fundus Appearance: Optic disc oedema is typically hyperaemic or segmental (swollen superiorly with an inferior field defect, or vice versa), often accompanied by flame-shaped peripapillary splinter haemorrhages. Over 6 to 8 weeks, the swelling resolves, giving way to sectoral or generalized optic atrophy.
Fellow Eye Examination: Crucially, funduscopy of the fellow unaffected eye demonstrates the characteristic "disc at risk" (absent cup, crowded disc).
Natural History & Management
Visual Acuity Course: Unlike AAION, spontaneous visual acuity improvement of ≥ 3 \ge 3 ≥ 3 Snellen lines occurs in approximately 40% of NAION patients over the first 3 to 6 months. However, visual field defects rarely resolve.
Recurrence in the Same Eye: True recurrence in the previously affected eye is extremely rare ( < 5 % <5\% < 5% ), because the resultant optic atrophy ("pseudo-cup") decompresses the scleral canal, eliminating the crowded compartment effect.
Fellow-Eye Involvement Risk: The 5-year risk of NAION developing in the fellow eye is approximately 15% to 20% .
Treatment Evidence: The landmark Ischemic Optic Neuropathy Decompression Trial (IONDT) demonstrated that optic nerve sheath decompression surgery is completely ineffective and potentially harmful in NAION (surgical patients fared worse than observed controls). No medical therapy (including corticosteroids, aspirin, or neuroprotective agents) has been conclusively proven to reverse visual loss in randomised controlled trials. Clinical management focuses on modifiable risk factors: screening and treating sleep apnoea, addressing smoking, diabetes and lipids, and reviewing blood-pressure patterns and potentially associated medicines with the treating physician. Do not impose an automatic antihypertensive timing change or lifelong drug prohibition.
Diagnostic Comparison: AAION (GCA) vs. NAION
The following table contrasts the essential features required to differentiate AAION from NAION:
Diagnostic Domain Arteritic AION (GCA) Non-Arteritic AION (NAION)
Underlying Etiology Systemic granulomatous necrotising vasculitis Microvascular hypoperfusion / crowded disc compartment syndrome
Patient Age Almost exclusively ≥ 50 \ge 50 ≥ 50 years (mean 75 years) Over 50 years (mean 60-65 years); occasionally younger
Visual Acuity Loss Catastrophic (count fingers to NLP in > 60 % >60\% > 60% ) Mild-to-moderate (20/20 to CF; ≥ 20 / 60 \ge 20/60 ≥ 20/60 in > 50 % >50\% > 50% )
Onset Timing Sudden, any time of day; amaurosis fugax warning Sudden, classically upon awakening ( "morning discovery" )
Fundus Appearance Chalky-white "pallid" disc oedema ; cilioretinal artery occlusion Hyperaemic or segmental disc oedema; peripapillary splinter bleeds
Fellow Eye Optic Disc Normal optic disc with normal physiological cup "Disc at risk" (absent or small cup, cup-to-disc ratio ≤ 0.2 \le 0.2 ≤ 0.2 )
Systemic Symptoms Jaw claudication, scalp pain, headache, PMR, weight loss Absent; history of hypertension, diabetes, OSA, PDE-5 use
Westergren ESR Markedly elevated (often > 50 − 100 mm/hr >50-100\text{ mm/hr} > 50 − 100 mm/hr ) Normal for age (occasionally mildly elevated due to comorbidities)
C-Reactive Protein Markedly elevated ( > 2.45 mg/dL >2.45\text{ mg/dL} > 2.45 mg/dL or > 10 mg/L >10\text{ mg/L} > 10 mg/L ) Normal
- Platelet Count Thrombocytosis ( > 400 × 10 9 /L >400 \times 10^9\text{/L} > 400 × 1 0 9 /L ) Normal
- Temporal Artery Biopsy Positive (granulomatous panarteritis, skip lesions) Normal
- Fellow Eye Risk Up to 50% within days/weeks if untreated 15% to 20% over 5 years
Acute Management Emergency: IV Methylprednisolone 1000 mg/day for 3 days Observation; control vascular risk factors; no nighttime antihypertensives
NAION Risk Review
A crowded fellow disc and sectoral swelling support NAION in the appropriate setting after excluding GCA and other causes. Address vascular risk, smoking and sleep apnoea with the physician. Nocturnal hypotension and some medicines are possible associations, not proof of causation in every case. Do not automatically change antihypertensive timing or order lifelong cessation of a systemic drug without coordinated review. No established treatment reliably restores lost vision; recurrence and fellow-eye counselling should reflect individual risk.